ArticleNature communications2026
A NIR fluorotag reporter CETIF6a enables bright pan-tumor labeling and functional proteomic profiling.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor-seeking fluorescent dyes enable precise lesion localization by recognizing overexpressed receptors, providing a critical adjunctive technology for cancer histopathology. However, tumor heterogeneity and the poor understanding of targeting mechanisms limit their efficacy. Here we engineer CETIF6a, a click chemistry-compatible heptamethine cyanine dye, for multi-cancer targeting, intraoperative histopathology, and proteome-wide target identification. CETIF6a demonstrates margin delineation across multiple cancer types ( > 90% concordance with H&E staining). Quantitative proteomics reveals that the dye targets 5-15 times more tumor-specific proteins than in paracancerous tissues. Synergistic pan-cancer targeting is achieved through 491 conserved tumor-enriched proteins involved in ribosomal, proteasomal, and metabolic pathways, effectively overcoming heterogeneity. Mechanistic studies confirm that CETIF6a emits bright fluorescence upon covalent binding to targets via nucleophilic substitution at cysteine thiol residues within hydrophobic cavities. The modifiable scaffold of CETIF6a supports both intraoperative tumor diagnosis and functional targets profiling, providing a foundation for systematic probe optimization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.